Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
J Crit Care. 2010 Jun;25(2):287-93. doi: 10.1016/j.jcrc.2009.12.006. Epub 2010 Feb 10.
Heparin-induced thrombocytopenia (HIT) is commonly considered but rarely confirmed in critically ill patients. The 4Ts score (Thrombocytopenia, Timing of thrombocytopenia, Thrombosis, and oTher reason) might identify individual patients at risk of having this disorder.
The aim of the study was to evaluate the value of the 4Ts HIT score in comparison with the serotonin-release assay (SRA) in critically ill patients.
This study describes the combined results of 3 prospective studies enrolling critically ill patients who were investigated for HIT if platelets fell to less than 50 x 10(9)/L or if platelet counts decreased to less than 50% of the value upon intensive care unit admission. We confirmed HIT by a positive platelet SRA. We assigned a 4Ts score blinded to SRA results to all 50 patients investigated for HIT; those with positive SRA results were scored in duplicate.
Of 528 patients, 50 (9.5%) were investigated for HIT; 39 (78%) of 50 (64%-88%) of these patients were scored as "low probability" by 4Ts score and none had a positive SRA. Of 49 patients who underwent SRA testing because of thrombocytopenia, only 2 (4.1%; 0.5-14.0) had a positive SRA (1 with a moderate 4Ts score and 1 with a high 4Ts score). Therefore, the overall incidence of HIT confirmed by SRA was 2 (0.4%) of 528 (0.04%-1.4%).
Significant thrombocytopenia during heparin administration occurred in 9.5% of critically ill patients, but HIT was confirmed in only 4.1% of those undergoing testing, for an overall incidence of 0.4%. A low 4Ts score occurred in 78% of patients investigated for HIT; none of these patients had a positive SRA. We conclude that HIT is uncommon in critically ill patients and that the 4Ts score is worthy of further evaluation in this patient population.
肝素诱导的血小板减少症(HIT)在危重病患者中通常被认为存在,但很少被证实。4Ts 评分(血小板减少、血小板减少的时间、血栓形成和其他原因)可能可以识别出有发生这种疾病风险的个体患者。
本研究旨在评估 4Ts HIT 评分与血清素释放试验(SRA)在危重病患者中的价值。
本研究描述了 3 项前瞻性研究的综合结果,这些研究纳入了如果血小板降至<50×10(9)/L 或血小板计数降至入住重症监护病房时的 50%以下,则对 HIT 进行调查的危重病患者。我们通过血小板 SRA 阳性来确认 HIT。我们对所有接受 HIT 调查的 50 名患者进行了 4Ts 评分,且对 SRA 结果进行了盲法评估;对 SRA 结果阳性的患者进行了重复评分。
在 528 名患者中,有 50 名(9.5%)接受了 HIT 调查;其中 50 名(78%)患者的 4Ts 评分被评为“低概率”(64%-88%),且无 SRA 阳性。在因血小板减少而接受 SRA 检测的 49 名患者中,仅有 2 名(4.1%;0.5-14.0)SRA 阳性(1 名患者的 4Ts 评分为中度,1 名患者的 4Ts 评分为高度)。因此,通过 SRA 确认的 HIT 总发生率为 528 名患者中的 2 名(0.4%)(0.04%-1.4%)。
在接受肝素治疗的危重病患者中,血小板显著减少的发生率为 9.5%,但接受检测的患者中仅 4.1%被确认为 HIT,总发生率为 0.4%。在接受 HIT 调查的患者中,78%的患者的 4Ts 评分较低;这些患者无一例 SRA 阳性。我们得出结论,HIT 在危重病患者中并不常见,4Ts 评分在该患者人群中值得进一步评估。